User account menu Search Menu Home Investors Novartis Financial Data Product Sales Product Sales Full Year 2020 Product Sales The following table provides the top 20 Innovative Medicines Division product net sales in 2020 as well as the change compared to 2019: Brands Net Sales (USD m) % change (USD) Business Franchise Cosentyx 3,995 13% Immunology, Hepatology and Dermatology Gilenya 3,003 -7% Neuroscience Entresto 2,497 45% Cardiovascular, Renal and Metabolism Tasigna 1,958 4% Oncology Lucentis 1,933 -7% Ophthalmology Promacta/Revolade 1,738 23% Oncology Tafinlar + Mekinist 1,542 15% Oncology Sandostatin 1,439 -9% Oncology Jakavi 1,339 20% Oncology Xolair1 1,251 7% Respiratory Galvus Group 1,199 -8% Established Medicines Gleevec/Glivec 1,188 -6% Oncology Afinitor/Votubia 1,083 -30% Oncology Diovan Group 1,003 -6% Established Medicines Exforge Group 980 -4% Established Medicines Zolgensma 920 155% Neuroscience Ilaris 873 30% Immunology, Hepatology and Dermatology Kisqali 687 43% Oncology Exjade/Jadenu 653 -33% Oncology Votrient 635 -16% Oncology Net sales reflect Xolair sales for all indications. Related Links Product recalls Product and patient safety training Novartis production and manufacturing B-roll (Video) Novartis key multiple sclerosis product Gilenya® approved in China Novartis Navigate Patients and Caregivers Healthcare Professionals Researchers Job Seekers Journalists Investors Partners Suppliers Topics Clinical Trials COVID-19 Info Center ESG Explore Stories Diseases Locations Companies Sandoz Advanced Accelerator Applications Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience

User account menu Search Menu Home Investors Shareholder Information Shareholder Information General Meetings Find information about our General Meetings. Learn More Novartis Registered Shares Find information for holders of Novartis Registered Shares. Learn More American Depository Receipts (ADR) Find information for holders of Novartis American Depository Receipts. Learn More Share Buy-Back Find information about the Novartis share buy back program. Learn More Frequently Asked Questions Review key questions and answers about Novartis shares, general finance, ESG and investor relations services. Learn More Novartis Navigate Patients and Caregivers Healthcare Professionals Researchers Job Seekers Journalists Investors Partners Suppliers Topics Clinical Trials COVID-19 Info Center ESG Explore Stories Diseases Locations Companies Sandoz Advanced Accelerator Applications Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience